Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens
- Conditions
- Cataract
- Interventions
- Device: IOL Implantation
- Registration Number
- NCT01615861
- Lead Sponsor
- Bausch & Lomb Incorporated
- Brief Summary
The objective of this study is to evaluate clinical outcomes following sub-2 mm micro-incision cataract surgery (MICS) and intraocular lens (IOL) implantation. This study is evaluated in two Phases
* V4 (6M) endpoint: primary analysis
* V5 (12M) and V6 (34M): EPCO score and Nd Yag incidence analysis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 103
- Subjects must have clear intraocular media other than cataract in the study eye.
- Subjects must have a clinically documented diagnosis of age-related cataract that is considered amenable to treatment with micro-incision phacoemulsification cataract extraction in the study eye.
- Subjects with ocular malformation in the study eye.
- Subjects who have had previous surgery in the study eye.
- Subjects with uncontrolled glaucoma in either eye.
- Subjects with any anterior segment pathology for which micro-incision phacoemulsification cataract surgery would be contraindicated
- Subjects using medications known to potentially complicate cataract surgery.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description IOL implantation IOL Implantation Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
- Primary Outcome Measures
Name Time Method Visual Acuity 6 months Corrected distance visual acuity (CDVA)
- Secondary Outcome Measures
Name Time Method Lens decentration 6 Months Laser capsulotomy 24 Months Removal of post-surgical, posterior capsular opacification (PCO)
Incision size 6 Months Incision size before and after implantation
Refraction 6 Months Manifest refraction spherical equivalent. Accuracy to target refraction
Visual Acuity 6 Months Uncorrected distance visual acuity (UDVA)
EPCO 24 Months 3 mm evaluation of posterior capsule opacification (EPCO) score
Trial Locations
- Locations (1)
Bausch & Lomb
🇫🇷Labege, France